Ezra's Notes Checked November 16, 2026
Investor Holdings

By @ezracrangle

← David Rolfe, latest 13F

Bristol-Myers Squibb

In David Rolfe's portfolio · Wedgewood Partners

Ticker BMY

Not in the portfolio as of Q2 2026. Every quarter it shows up in a Wedgewood Partners 13F, newest first.

QuarterActivitySharesWeightPriceValue
Q1 2023 Sell 0  
Q4 2022 Reduce 23% 4,175 0.1% $71.86 $300K
Q3 2022 Reduce 8% 5,425 0.1% $70.97 $385K
Q2 2022 Reduce 14% 5,925 0.1% $76.96 $456K
Q1 2022 Add 48% 6,925 0.1% $72.92 $505K
Q4 2021 Reduce 12% 4,675 0.0% $62.25 $291K
Q3 2021 Reduce 6% 5,300 0.0% $59.06 $313K
Q2 2021 Reduce 93% 5,625 0.1% $66.67 $375K
Q1 2021 Reduce 82% 75,835 0.7% $63.12 $4.8M
Q1 2021 Sell 0  
Q4 2020 Reduce 6% 414,057 3.8% $62.03 $25.7M
Q4 2020 Reduce 7% 122,750 0.0% $0.68 $84K
Q3 2020 Add 18% 439,319 4.2% $60.29 $26.5M
Q3 2020 Reduce 2% 131,557 0.0% $2.24 $295K
Q2 2020 Add 44% 373,781 3.7% $58.80 $22.0M
Q2 2020 Reduce 10% 134,729 0.1% $3.57 $481K
Q1 2020 Reduce 34% 259,180 2.7% $55.74 $14.4M
Q1 2020 Buy 148,901 0.1% $3.79 $565K
Q4 2019 Buy 391,442 2.5% $64.19 $25.1M

Price is the position's value divided by its shares, at the end of each quarter. Share counts are as filed; when a stock split happened, the change is measured on split-adjusted shares.